Nanobiotix Shares Drop 3.5% Despite Joining Euronext Tech Leaders
The French biotech continues another session in the red while the Paris stock market trends upward. This movement occurs on the same day as the announcement of its inclusion in the Euronext Tech Leaders segment. The digestion phase following the mid-May historical record continues.
Share Price Declines Despite Entry into Euronext Tech Leaders Segment
Nanobiotix shares fell by 3.34% to €31.86 at midday, while the SBF 120 index gained 0.60% during the session. The stock is among the largest declines in the broad index. This drop coincides with the day the biotech announced its integration into the Euronext Tech Leaders segment, an initiative launched in 2022 by Euronext to increase the visibility of growing technology companies among international investors. Over the past seven days, the stock has lost 13.05%. However, the annual performance remains spectacular, exceeding 768%, driven by clinical advancements around the JNJ-1900 candidate developed with Johnson & Johnson and by the share placement operation conducted at the end of May.
Stock Falls Below Its 20-Day Moving Average and Tests the 50-Day Moving Average Pivot
The stock price is now 14.88% below its 20-day moving average, located at €37.43, indicating that the short-term momentum has significantly deteriorated. However, the stock remains above its 50-day moving average at €31.24, a level that acts as an immediate pivot: breaking this level would pave the way to the support at €26.34. The RSI at 46 indicates a neutral configuration, without any overselling signal, which leaves the door open for the continuation of the digestion movement. The gap of more than 51% with the 200-day moving average, at €21.09, illustrates the extent of the rally over twelve months. The behavior of the price around the 50-day moving average will be crucial for the future of the movement.
